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ABSTRACT  
 
Background 
Previously developed models in ophthalmology have generally used a Markovian structure. There are a 
number of limitations with this approach, most notably the ability to base patient outcomes on best-
corrected visual acuity (BCVA) in both eyes, which may be overcome using a different modelling 
structure. Simulation modelling allows for this to be modelled more precisely, and therefore may 
provide more accurate and relevant estimates of the cost-effectiveness of ophthalmology interventions. 
 
Objective 
 
This study aimed to explore the appropriateness of simulation modelling in ophthalmology, using the 
disease area of wet age-related macular degeneration (wAMD) as an example. 
 
Methods 
A de novo economic model was built using a patient-level simulation, which compared ranibizumab to 
aflibercept in wAMD. Disease progression was measured using BCVA. Health-related quality of life 
(HRQoL) was estimated using a regression analysis linking BCVA in each eye to utility. The analysis 
was from the perspective of the National Health Service in the UK. Five different regression models 
were explored and were based on BCVA in either one eye or both eyes.  
 
Results 
The model outputs provide some evidence to support the hypothesis that the analyses using the two-eye 
models for estimating HRQoL generate a more accurate estimation of incremental quality-adjusted life 
years (QALYs) associated with the positive treatment effect for ranibizumab versus aflibercept. 
Second-order analysis broadly supported these findings, and showed that the variation in incremental 
costs was slightly lower than in incremental QALYs. The second-order analysis estimated similar 
incremental costs and a greater overall variation in incremental QALYs than the first-order analysis, 
suggesting important non-linearities within the model. 
 
Conclusions 
This analysis suggests that patient-level simulation models may be well suited to representing the real-
world patient pathway in wAMD, particularly when aspects of disease progression cannot be 
adequately captured using a Markov structure. The benefits of a simulation approach can be 
demonstrated in the modelling of HRQoL as a function of BCVA in both eyes. 
 
Key Points for Decision Makers 
x Patient-level simulation modelling may be a technique well-suited to representing the patient 
pathway and disease progression in ophthalmology. 
x An analysis of two NICE-approved treatments for wAMD provides an example of the benefits 
of simulation modelling over cohort (Markov) modelling in this disease area.  
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1. Introduction 
 
1.1 Background 
To date, many economic models for evaluating interventions in ophthalmology conditions, such as wet 
age-related macular degeneration (wAMD), retinal vein occlusion, diabetic macular oedema (DMO) 
and pathologic myopia, have followed a Markov structure, in which patients or populations can move 
between defined health states over successive time periods or cycles. Reviews of cost-effectiveness 
evidence are undertaken as part of NICE technology appraisals, which demonstrate that the majority of 
previously conducted analyses used a cohort framework [1-7]. In ophthalmology, health states are 
typically based on best corrected visual acuity (BCVA), as measured in clinical trials, with 
improvement of BCVA a key goal of treatment. BCVA differs in both eyes at different time points, and 
has further been shown to be a determinant of health±related quality of life (HRQoL), with severe 
visual impairment associated with excess mortality [23]. Current cohort modelling methods may 
restrict the ability to reflect the BCVA change in both eyes at different time points. This is related to 
the memoryless nature of Markov modelling, and to the necessity to construct discrete health states for 
each event or combination of events. Markov models do not have the ability to retain memory of a 
pDWLHQW¶V previous health states without the introduction of additional health states or tunnel states, and 
so lack the ability to effectively incorporate the development of bilateral involvement. Moreover, 
incorporating treatment switch or treatment discontinuation without the addition of more health states 
limits the applicability of the cohort models.  Models which attempt to model both eyes explicitly are 
typically associated with a large number of health states, even without the incorporation of any tunnel 
states to capture these aspects of the treatment pathway [1-2]. 
 
Due to these limitations of a cohort model, a patient-level simulation approach may be considered a 
suitable alternative. This allows for modelling a single patient at a time, generating clinical events and 
treatment switches according to the treatment status in both the eyes independently, and the time from 
the start of treatment. It also allows for the occurrence of any number of events such as changes in 
BCVA over time in each eye, fellow-eye involvement, and improvement in HRQoL as a function of 
BCVA in both eyes. Recurrence could also be modelled based on a known prognostic variable a priori 
due to the ability of a simulation model to capture patient history. The major difference compared to 
cohort models is the absence of defined health states and the ability to model both eyes explicitly.  
 
1.2 Study objectives 
In this study, wAMD has been used as an example to illustrate the points highlighted above. There are 
two intravitreal VEGF inhibitors currently licensed in Europe and approved by the National Institute 
for Health and Care Excellence (NICE) for the treatment of wet AMD in the UK: ranibizumab 
(Lucentis®, Genentech Inc./Novartis) and aflibercept (Eylea®, Bayer plc) [8-9]. When conceptualising 
the economic analysis, previous technology appraisals undertaken by NICE were evaluated, 
specifically considering the modelling methods used and the critique by the Evidence Review Group 
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(ERG) [1-3]. Historically, manufacturer models have explicitly assumed that only the better-seeing eye 
(BSE) was treated, even though the clinical data on which the model was based were drawn 
predominately from people whose worse-seeing eye (WSE) had been treated.  Subsequent models 
attempted to incorporate WSE data in a limited capacity. Analyses based on either the BSE and WSE 
alone have been demonstrated to produce different model outcomes (such as QALY gains), partly 
because HRQoL of people with visual impairment is associated primarily with vision in the BSE [10-
11]. This is a major limitation in ophthalmology models, as improvements in SDWLHQWV¶ vision function 
and HRQoL are recognized as the most important outcomes of any ophthalmology treatment. It can be 
expected that models based on one eye only will systematically underestimate the potential QALY 
gains associated with treatment. Disease activity can manifest in either the BSE or the WSE (or indeed 
both), and an analysis linking HRQoL to VA in only one of these eyes will only capture the QALY 
gains associated with improvement in VA if the utility model corresponds to the eye that is being 
treated. 
 
The objective of this study was to develop a patient-level simulation model to address the limitations 
mentioned above, with the purpose of informing the optimal approach to modelling cost-effectiveness 
in ophthalmology submissions to Health Technology Assessment (HTA) bodies such as NICE. 
 
 
2. Methods 
2.1 Overview 
The analysis assessed the cost-effectiveness of two treatments for wAMD, ranibizumab and aflibercept, 
which were both assumed to be administered via a pro re nata (PRN) dosing schedule. Outcomes were 
assessed in a population representative of those with wAMD, with baseline characteristics based on 
patients in the EXCITE clinical trial [12]. Costs were assessed from the perspective of the National 
Healthcare Service (NHS) and personal social services (PSS) in the UK.  The model was designed to 
capture both first-order (individual patient) and second-order (parameter) uncertainty [37]. 
Disease progression in wAMD can be characterised by deterioration in vision in the affected eye. A 
proportion of patients will experience the disease in both their eyes. Within the model, BCVA (as 
assessed by number of letters read on an Early Treatment Diabetic Retinopathy Study (ETDRS) visual 
acuity chart) was used as a marker of disease progression. This measure ranges from 0 to 100, with 0 
being completely blind and 100 being perfect vision. Change in BCVA was modelled independently in 
each eye, including when the patient has bilateral disease and is treated in both eyes.   
The response to treatment and ongoing impact on disease activity can be characterised by an initial 
response to treatment, followed by a period of disease stabilisation. After this, vision has been 
demonstrated to deteriorate gradually over time. As such, disease progression was modelled in several 
stages. Discontinuation of active treatment can occur in a small proportion of patients, due to persistent 
deterioration in visual acuity, or an inadequate response to treatment. 
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2.2 Modelling approach 
Within this analysis, a patient-level simulation model was developed. A decision-analytic model was 
developed in Microsoft Excel 2010®. Figures 1a and 1b present a diagrammatical representation of the 
model flow. 
 
The procedure by which the model run was performed is as follows: (i) a patient was drawn at random 
from a pool of patient-level baseline characteristics; (ii) the change in BCVA for this patient was 
evaluated in each model arm at each monthly cycle; (iii) costs and QALYs were assigned to the 
patient; (iv) a new patient was drawn from the original pool and the process from (i) to (iii) repeated; 
(v) the mean costs and QALYs were estimated for the cohort. Patients with an unaffected fellow eye 
were assumed to have a probability of the fellow eye becoming affected [13].The presence of bilateral 
disease was identified at the start of the cycle, and then BCVA change was estimated for the fellow eye 
based on presence of disease. Costs and QALYs were assigned as a patient entered the health state. 
Half-cycle correction was not applied to model outcomes ± given the short cycle length, this was felt to 
have a negligible impact on the results. 
 
Patients were assumed to receive either ranibizumab or aflibercept over a maximum of 5 years, 
although the model continued to assess outcomes over the patient lifetime.  
 
Outcomes were modelled over a remaining-lifetime time horizon. Following NICE recommendations, 
future costs and health outcomes were discounted at 3.5% per annum. 
 
Whilst the focus of the study was not specifically to establish the relative cost-effectiveness of each 
intervention, efforts were made to ensure that all model inputs and assumptions were suitable and 
clinically justifiable. 
 
2.3 Patient population 
 
Baseline patient characteristics were based on patients in the EXCITE Phase III study, a trial 
comparing two regimens of ranibizumab [12]. This study was considered reflective of the wAMD 
patient population and was one of the few studies with available data on BCVA in both eyes, rather 
than just the study eye. The starting characteristics of each patient being entered into the model 
simulation were assigned by randomly selecting actual individual patient records of baseline 
characteristics from EXCITE, in order to preserve realistic correlation between characteristics. In the 
trial, the mean starting age of patients was 76 years and the likelihood of bilateral disease at the start of 
the trial was 18.54%. Mean BCVA in the study eye and fellow eye was 56 and 55 respectively.  
 
2.4 Model parameters 
2.4.1 Clinical effectiveness  
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Disease progression was incorporated within the model as the mean change in BCVA per month. The 
use of a simulation model allowed for BCVA to be estimated directly as a continuous variable, rather 
than artificially dividing into a number of mutually exclusive health states (as would be the case if a 
cohort model, such as a Markov model, was adopted). This adds to the precision and granularity of 
change in BCVA compared with the Markov approach, where it is recommended to limit the number 
of health states used [14]. With a cohort model with discrete health states, in order to be able to include 
all viable study data, it would have been necessary to transform the data so that it measured the 
probability of achieving each health state in the model. This would require making assumptions about 
the data and would introduce additional uncertainty and potential errors. It would also diminish the 
viability of incorporating synthesized evidence from a network meta-analysis (NMA) with the same 
level of accuracy, due to additional assumptions needing to be made and not having access to patient-
level data sets for all relevant comparators. The present approach circumvents this need by using the 
outcome from a NMA directly. 
 
Disease progression was modelled in several stages. Monthly BCVA change for each comparator was 
estimated by a random draw from a normal distribution with a mean and standard deviation. The 
assumption of normality is supported by evidence from the clinical trials comparing ranibizumab with 
aflibercept [16]. For example, mean change in BCVA at 52 weeks in the ranibizumab arm of the VIEW 
1 study is 8.1 letters with a standard deviation of 15.3 letters. If response was normally distributed this 
would suggest that 32.6% of patients would experience an increase of 15 or more letters and 6.6% 
would experience a decline of more than 15 letters. These figures are in line with those reported in the 
study which reports that 30.9% of patients experienced an increase of 15 or more letters and 5.6% a 
decline of more than 15 letters. In the initial period up to 24 months, treatment response to ranibizumab 
was based on data from the IVAN study (the discontinuous treatment arm) [15]. Patients in the IVAN 
trial had similar baseline characteristics to those used in the EXCITE study  (mean age of 77.7); 
however, the mean BCVA in the study was slightly higher than that use in this analysis (mean BCVA 
of 61.4). The relative effectiveness of ranibizumab versus aflibercept was modelled using data from a 
NMA of randomized controlled trials [17] and was estimated for every month for 24 months using 
methods outlined in Ding and Fu [18]. The studies used to inform the NMA are provided in the 
Supplementary Material (Table S1). Details of the clinical effectiveness parameters are provided in the 
Supplementary Material (Table S2). 
 
The model assumed that treatment response was independent over time, that is, treatment response in a 
given month was not correlated with treatment response in previous months. Where both eyes were 
affected, treatment response in each eye was modelled independently. It was assumed patients could 
discontinue treatment at any time in the five-year period. Probabilities of discontinuation were based 
on a naïve comparison of the rate of withdrawal not due to death in the IVAN trial [15] for 
ranibizumab and the VIEW trial [19] for aflibercept.  
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Beyond 24 months and up to 60 months, BCVA was assumed to remain constant, an assumption 
validated and implemented within a previous NICE appraisal [1]. After this period or after treatment 
discontinuation, BCVA was modelled using natural history data for wAMD patients [20]. Vision loss 
in an unaffected eye was modelled using data on normal vision loss taken from a meta-analysis of data 
[21-22].  
 
Adverse events relating to treatment were excluded from the analysis. These were considered to be 
equivalent between treatment arms, and the VIEW trials found there to be no meaningful differences in 
adverse event rates [16,19].  
 
2.4.2 Quality of life 
HRQoL may be influenced by visual acuity for a number of reasons. It may be related to the vision in 
one eye only (either the WSE or the BSE). It is more likely to be a function of visual acuity in both 
eyes, with the relative differences between the eyes being a possible influence. Becoming legally blind 
may also impact upon the SDWLHQW¶V wellbeing due to the psychological significance of the event, as 
well as more pragmatic factors (e.g. moving to a care home, loss of freedom due to not being able to 
drive). These factors are difficult to capture in a one-eye model, which has been used in many previous 
Markov models. 
 
Quality of life was estimated using a de novo regression analysis of a real-world dataset obtained from 
Czoski-Murray (2009) [23], a study that used contact lenses to simulate the effect of visual impairment. 
Within the regression analysis a number of models were considered, whereby quality of life was a 
function of visual acuity in the BSE alone, WSE alone, visual acuity in both eyes separately, visual 
acuity in both eyes with interaction term, visual acuity in both eyes with an interaction term and a 
blindness threshold (Supplementary Material, Table S3). The blindness threshold was implemented, 
where an additional utility decrement was applied, when patients had a BCVA of less than 35 in both 
eyes. The impact of using each of the five regression models was explored in the analysis.  Further 
details of the regression methods are provided in Appendix 1 of the Supplementary Material.  
 
2.4.3 Costs and resource use 
A summary of unit costs and resource use in the model is provided in the supplementary material 
(Table S4 for unit costs, Table S5 for treatment and monitoring schedule). Costs from earlier years 
were inflated to 2014 prices using the Hospital and Community Services Inflation Index [24].  Costs 
were based on a UK healthcare provider (NHS and PSS) perspective. The key costs considered in the 
analysis included drug costs, costs of administering treatment and monitoring costs. Costs were also 
applied as patients entered the blindness health state.  
 
Patients were treated and monitored using a PRN schedule, and were based on previously published 
estimates of mean number of visits per year over the 5-year treatment period [25-27].  The mean 
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treatment and monitoring cost per cycle was estimated for each year of treatment, and applied to 
patients while on treatment. 
 
Costs of blindness were applied when both eyes had a BCVA below 35 letters. Treatment was 
terminated if the treated eye reached a BCVA below 35 letters. Resource utilisation in patients who 
were blind was based on data in a published study, a systematic review and economic evaluation of 
photodynamic therapy for the treatment of wet AMD [28]. Each resource associated with treating 
patients with blindness was applied to a varying proportion of patients [29]. Blind registration was 
applied as a one-off cost when patients entered the blindness state for the first time.  
 
2.4.4 Mortality 
Age-specific all-cause mortality for the general population was estimated from UK life tables [30]. To 
reflect the increased mortality risk in patients who have some degree of impaired vision, a relative risk 
(RR) was applied to the background mortality rate [31]. For individuals with severe visual impairment, 
defined as BCVA lower than 35 in both eyes, a RR of 1.54 was applied. For individuals with some 
visual impairment (defined as either eye having BCVA lower than 55), a RR of 1.23 was applied.  For 
the impact on mortality associated with visual impairment to be modelled adequately, the BCVA in 
both eyes should be estimated explicitly. 
 
2.5 Validation 
 
BCVA change in the model was validated by comparing the mean BCVA change in each arm with the 
BCVA change observed in the original source (the IVAN trial [15] for BCVA progression in patients 
on ranibizumab, and the NMA [17] for the difference in BCVA between aflibercept and ranibizumab 
patients), over the first 24 months of treatment.  
 
2.6 Analysis 
 
The primary outcome of the analysis was the mean cost and the mean number of QALYs for each 
intervention.  
 
The base case analysis incorporated individual patient, or first-order, uncertainty. The probabilistic 
sensitivity analysis incorporated parameter, or second-order, uncertainty in addition to first-order 
uncertainty [14].  
 
Results of the first-order (base case) analysis were based on 200,000 simulated patients over a lifetime 
time horizon, to ensure stability. A number of scenarios were undertaken, based on different methods 
of estimating HRQoL. The different analyses included: (i) Model 1: HRQoL as a function of BCVA in 
the BSE; (ii) Model 2: HRQoL as a function of BCVA in the WSE; (iii) Model 3: HRQoL as a function 
of BCVA in both eyes (no interaction); (iv) Model 4: HRQoL as a function of BCVA in both eyes 
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(with interaction); and (v) Model 5: HRQoL as a function of BCVA in both eyes (with interaction and 
a blindness threshold). In this analysis, parameters that were varied stochastically include baseline 
patient characteristics and response to treatment. Event occurrence (death, discontinuation, 
development of bilateral disease) was determined stochastically, based on the point estimate of the 
parameter. Monte Carlo error (MCE) was assessed at different number of iterations of the model [32]. 
 
Second-order uncertainty was assigned to the point estimate of key variables, including baseline 
characteristics, treatment response, the coefficients in the utility regression analysis, and the relative 
risk of mortality. A total of 100 probabilistic estimates of cost-effectiveness were generated, each based 
on 10,000 simulations of the model. Each of the 100 probabilistic estimates was based on a randomly 
generated point estimate (mean value) of the key parameters. Details of the parameters included in the 
second-order analysis and their variation are provided in the Supplementary Material (Table S6). 
  
3. Results 
The results of this study demonstrate that a simulation modelling approach provides a feasible option 
for evaluating the cost-effectiveness of ophthalmology interventions.  
 
3.1 First-order (individual patient) uncertainty: base case analysis 
Results of the base case analysis are presented in Table 1.  
 
The total costs and life-years gained were very similar in both treatment arms, with the small decrease 
for aflibercept reflecting the higher mortality rate in patients with lower BCVA. 
 
Results for the three two-eye models were broadly similar. Total QALYs were highest in the model 
based on the BSE only (model 1) for estimating HRQoL, and lowest in the model based on the WSE 
only (model 2).  The one-eye model based on BSE only (model 1) resulted in the largest number of 
incremental QALYs. 
 
3.2 Second-order (parameter) uncertainty: probabilistic sensitivity analysis 
 
The mean incremental QALYs and the mean incremental costs in the second-order analysis were 
similar to those observed in the first-order analysis.  There was slightly greater variation in incremental 
QALYs than incremental costs in the second-order analysis (Table 2). Figure 2 presents the scatterplot 
for the probabilistic results of Model 4. Ranibizumab had a >95% probability of cost-effectiveness at 
all willingness-to-pay threshold values, in all five scenarios. 
 
3.3 Visual acuity 
The simulation model can be demonstrated to model BCVA progression similarly to that observed in 
the studies on which the input parameters were based (Figures 3a and 3b). Baseline BCVA in the 
model was consistent with that of the population on which they were modelled: the mean baseline 
BCVA of the EXCITE study was 56.93, compared with 56.90 in the model. Consistent with the results 
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of the NMA, the model predicted a slight treatment benefit in favour of ranibizumab compared with 
aflibercept. Modelled BCVA in the ranibizumab arm was similar to that observed in the IVAN trial, 
although the modelled mean BCVA was lower towards the end of the 24-month period. Predicted 
differences in BCVA between the ranibizumab and aflibercept arms were broadly similar to those 
estimated in the NMA, although there was some observed variation towards the end of the study 
period.  
 
A limitation of simulation modelling is the additional computational requirements to generate sufficient 
numbers of patients to estimate the mean model outcomes, and the resulting time for the model to run. 
A stabilisation test was undertaken: after very few (approximately 5,000) iterations of the model, the 
variability in the mean result is reduced, and the mean result converges to within 1% of the base case 
result. The MCE was demonstrated to decrease with increasing number of iterations. The MCE for 
each analysis is presented in the Supplementary Material (Table S7).  
 
4. Discussion 
 
4.1 Overview 
The results of this economic evaluation suggest that simulation modelling is a suitable alternative for 
modelling in ophthalmology. The analysis provides some evidence to support the hypothesis that health 
economic models based on the two-eye regression models may generate a more accurate estimation of 
incremental QALYs for the comparison of ranibizumab vs. aflibercept in wAMD. The model based on 
the BSE eye only provides a substantially higher estimate of total QALYs compared to the model 
based on the WSE only.  A one-eye model is likely to misrepresent QALY gains, as it will only capture 
the benefit of treatment when the eye being treated is the eye used in the utility regression. A two-eye 
model is able to capture improvement in vision regardless of the eye it occurs in.  
 
4.2 Limitations 
 
There were some limitations associated with the dataset used to estimate the relationship between 
vision and HRQoL. Data was collected by Czoski-Murray in a population of healthy subjects with no 
ocular pathology, with HRQoL elicited using the time trade off (TTO) technique [23]. Subjects were 
younger than those who typically present with wAMD, and more likely to be employed and educated 
to degree-level than the general population. The utility estimate for patients with high BCVA is higher 
than one may expect for patients with wAMD of this age. It is unclear whether the Czoski-Murray 
dataset provides sufficient variation between best and worst seeing eyes to clearly distinguish between 
the models, and therefore the difference between the best and worst seeing eyes may be minimal 
compared with the differences seen in patients with AMD. Due to these factors, the study population 
was not considered to be representative of the wAMD population, and it may be that the resulting 
dataset does not capture the impact of HRQoL adequately. The Czoski-Murray dataset was the only 
HRQL dataset that we had access to which collected BCVA data in both eyes. It has also been 
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previously used in a number of NICE technology appraisals ± while it was noted that there were 
limitations associated with the study, including issues around generalisability to the wet AMD 
population, it was considered to be the most appropriate source of utility data [9]. A more appropriate 
dataset that has been collected from representative patients with ocular disease may show a more 
definitive impact of using different utility models. However, the authors of this study are unaware of 
any patient-level datasets where HRQoL and BCVA in both eyes were collected and are readily 
available, particularly in a format that is suitable for economic modelling purposes. The availability of 
such data would also allow further investigation of how vision in both eyes contributes to overall 
HRQoL which would allow the advantages of a true two eye model to be further leveraged. Previous 
studies undertaken in representative patients have established the link between BCVA in the BSE and 
HRQL [33,34]. A comparison of the utilities in these studies with those elicited in the Czoski-Murray 
study found higher estimates of overall variation in HRQL in the two studies of representative patients. 
We would welcome work to validate our utility analysis using a real-world dataset.  
 
The MCE has been estimated for total costs and QALYs in the ranibizumab arm. It is normally 
recommended that MCE should be less than 5% of the mean value of the main outcome of interest: 
after 200,000 iterations, the MCE around total QALYs is 0.006, which is approximately 0.1% of the 
total QALY value and approximately 15% of the mean QALY difference between the two 
comparators.  As a result, it is possible that at least some of the difference between the comparators 
could be attributable to MCE.  
 
There is some evidence to suggest that contrast sensitivity (CS), rather than BCVA, is key to HRQL in 
ophthalmology [35]. However, CS is usually a secondary outcome in clinical trials of wAMD and is 
often not reported in the appropriate manner to enable economic modelling. Further, without an explicit 
link between CS and blindness, it would be challenging to incorporate all relevant costs and resource 
use into an analysis.  
 
A further important limitation of the model is that changes in BCVA are not correlated over time. In 
reality, one would expect BCVA progression to follow some form of autoregressive process rather that 
exhibiting random changes from month to month. This limitation would also be present in a Markov 
model in which transitions were fixed over time, and is not specific to simulation modelling. A possible 
extension to the model we present would be, therefore, to seek to model this process and for changes in 
BCVA to follow an autoregressive process whereby the change in BCVA at a particular time point is 
dependent upon changes at previous time points and possibly on baseline characteristics.  If appropriate 
source data were available, this could potentially provide a further advantage of a simulation model 
over a Markov model as this would be very difficult to implement in a Markov model.  
 
Similar conclusions to the first-order analysis were reached in the second-order analysis, although 
some variation was observed. The second-order analysis estimated similar incremental QALYs but 
lower incremental costs than the first-order analysis. A number of parameters were based on mean 
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values in the first-order analysis but varied in the second-order analysis, thus suggesting that there are 
important non-linear relationships between variables contained within the model, including mortality 
associated with aging, and the treatment effect over time. When there is a non-linear relationship 
between patient characteristics and model outputs, the mean of inputs cannot be used to evaluate the 
mean of the outputs. This is a further a limitation of Markov models in this context, which are based on 
mean cohort characteristics. 
 
4.3 Strengths 
 
Individual patient simulation models offer significant additional flexibility over Markov models 
allowing for the incorporation of two eyes into the model in an easy and transparent way, which results 
in a higher face validity of the model. Quality of life was estimated using a de novo regression analysis 
of a real-world dataset obtained from Czoski-Murray (2009) [23]. Thus, HRQL is based on the person 
as a whole rather than any individual components, and so is intuitively linked to the BCVA in both 
eyes. This is supported by the different outcomes of models based on the BSE or the WSE only. This 
ability to model both eyes independently is particularly important in wAMD where bilateral 
involvement is common, but is also relevant even where there is no bilateral involvement as it allows 
for incorporation of VA in an untreated eye. This is important as HRQoL is likely to be a function of 
vision in both eyes.  
 
An individual-patient approach also offers a number of further advantages. Firstly, because it models 
events rather than states, discontinuation and blindness can be modelled more naturally. Patient history 
can be captured more readily, allowing for aspects like one-off costs (blindness registration) to be 
incorporated in a more transparent manner. This aspect of the treatment pathway is difficult to capture 
in a Markov model given its memoryless properties (patients newly entering the blindness state are 
indistinguishable from those who have been there for at least one cycle). Secondly, because the model 
does not use health states it allows BCVA to be modelled on a continuous scale rather than being split 
into discrete health states in which patients are assumed to have the same HRQoL. This allows the 
potential benefits of interventions to be more accurately modelled and allows for effectiveness data to 
be incorporated in a more transparent way, including estimates derived from indirect evidence via an 
NMA. It also allows for non-linear relationships between visual acuity and both benefits and costs to 
be incorporated more accurately both increasing precision and the accuracy of predicted benefits and 
costs. Further, these gains in the precision and accuracy of predicted benefits and costs can be obtained 
without a significant increase in model complexity and therefore the transparency of the model is 
maintained.  
 
The analysis has been demonstrated to capture BCVA progression relatively precisely over the study 
period (Figure 3). While there is some degree of divergence towards the end of the study period, this 
may be due to factors such as the incorporation of discontinuation in the model and the resulting 
impact on BCVA, and the cumulative impact of Monte Carlo error. The model structure would also 
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allow for the correlation between baseline characteristics and treatment response throughout the study 
period, using the method of multivariate normality, although the authors did not have access to the 
appropriate data (the covariance between each pair of parameters) at the time of the study in order to 
implement this method. 
 
4.4 Previous economic analyses in ophthalmology 
To our knowledge, this study is the first economic evaluation for ophthalmology that has been 
developed using an individual simulation modelling approach rather than a Markov model. Previous 
economic evaluations using Markov models have been subject to criticism when reviewed by NICE, 
and were considered to accurately reflect vision in a single eye only. The NICE submission for 
aflibercept in wAMD was considered to inadequately model two eyes, leading to NICE rejecting this 
part of the analysis, using it as single-eye model only [2]. A Markov model was developed for the 
aflibercept submission for the treatment of DMO [6]. The analysis attempted to model both eyes 
explicitly, and as such the model included a large number of unique health states to allow for all 
combinations of BCVA in the study and fellow eye. Given the large amount of data that would be 
required to estimate transition probabilities between each health states, the model estimated 
probabilities whereby movement between health states was restricted and were constant across all 
health states. While this is likely the most practical approach to modelling two eyes in a Markov 
model, there are a number of limitations of modelling in this way. Firstly, the lack of granularity by 
using discrete health states to represent BCVA progression; secondly, the ceiling effect experienced 
through use of constant probabilities across health states (whereby patients in the highest health states 
would be µXQDEOH¶ to improve, even though the data suggest that a given proportion will do so, 
resulting in improvement in patients with a high BCVA being underestimated and the average VA 
score over time gradually falling below the observed value), and finally the complexities of using a 
large number of health states (difficulty in assessing and error-checking the model). The impact of 
ceiling effect is likely to be more pronounced where there are few health states. Increasing the number 
of health states, however, can rapidly increase model complexity and place heavy demands on input 
data such that the number of observations on which transition probabilities are estimated from becomes 
very small. 
 
A previous study comparing the outcomes of a Markov model and a simulation model for wAMD 
suggested that the incremental costs as estimated by a Markov model are lower, and the incremental 
QALYs are higher, than those estimated by a simulation model [36]. Since there is no gold standard for 
modelling in ophthalmology, it is difficult to ascertain which of the two model structures provides a 
more accurate estimate of the costs and QALYs that would be accrued in reality. It is likely that a 
simulation model is more accurate at estimating clinical and model outcomes, given its dynamic nature 
and ability to capture certain elements of the patient pathway.  
 
The benefits of simulation modelling are not restricted to ophthalmology. Simulation modelling has 
been demonstrated to be relevant in chronic and degenerative diseases where patient history is often 
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more important, such as in rheumatoid arthritis and cardiovascular disease. These benefit from being 
modelled with a structure that allows for sequences of treatments to be incorporated, and on time-since-
event probabilities to be incorporated. 
 
4.5 Conclusions 
These advantages of individual patient simulations outlined above may mean that the results of this 
analysis are more accurately estimated than in previously developed models. Additional studies 
comparing and verifying the results of a Markov model and a simulation model for the same decision 
problem, using the same data inputs, could be a useful direction for further research. The collection of 
bilateral utility outcomes from a representative population would allow the benefits of a patient 
simulation to be further exploited. 
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Figures 
 
Figure 1a: Model schematic ± disease progression in affected eye(s) 
 
 
Fig. 1a presents a diagrammatical representation of the flow of a patient through the model 
Abbreviations. BCVA: best-corrected visual acuity 
 
Figure 1b: Impact of BCVA on patient outcomes 
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Fig. 1b displays how the SDWLHQW¶V disease pathway (as measured by visual acuity) is linked to other 
model outcomes (including discontinuation, mortality, costs and quality of life)  
Abbreviations. BCVA: best-corrected visual acuity, SE: study eye, FE: fellow eye, QALY: quality-
adjusted life year 
 
 
Figure 2: Scatterplot of second-order analysis (ranibizumab vs aflibercept) 
 
 
Fig 2 presents the scatter plot of the second-order analysis. Results are presented for Model 4, the two-
eye model with an interaction term. Each red dot represents one estimate of cost-effectiveness 
(incremental QALYs and incremental costs for ranibizumab compared with aflibercept). The results 
show that ranibizumab was the dominant strategy (more effective and less costly) compared with 
aflibercept.  
RBZ adds 
QALYs 
RBZ more 
costly 
AFL adds 
QALYs 
AFL more 
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Abbreviations. QALY: quality-adjusted life-year. RBZ: Ranibizumab. AFL: Aflibercept. 
 
 
 
 
 
Figure 3a: Ranibizumab mean BCVA over time 
 
 
Fig 3a presents the mean change in BCVA for ranibizumab patients in their treated eye over the first 
24 months of starting treatment. The blue line represents the BCVA progression in the model, and the 
red line represents BCVA progression observed in the IVAN trial, on which the model was based. 
Abbreviations. BCVA: best-corrected visual acuity. 
 
Figure 3b: Aflibercept mean BCVA difference (relative to ranibizumab) over time 
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Fig 3b presents the mean difference in BCVA for aflibercept patients in their treated eye compared 
with ranibizumab patients over the first 24 months of treatment. The blue line represents the difference 
in BCVA in the model, and the red line represents the difference as estimated in the NMA on which the 
model was based. 
Abbreviations. BCVA: best-corrected visual acuity. NMA: network meta-analysis 
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Tables 
 
Table 1. Base case (first order) results 
 Mean cost Incremental  
cost Mean QALYs 
Incremental  
QALYs 
 Ranibizumab Aflibercept  Ranibizumab  Aflibercept  
BSE only 
(Model 1) £31,361 £39,745 -£8,384 5.772 5.728 0.044 
WSE only 
(Model 2) £31,362 £39,736 -£8,374 4.406 4.364 0.042 
Two eye, 
no 
interaction 
(Model 3) 
£31,351 £39,700 -£8,349 5.165 5.122 0.043 
Two eye, 
with 
interaction 
(Model 4) 
£31,386 £39,746 -£8,360 5.085 5.044 0.041 
Two eye, 
with 
blindness 
threshold 
(Model 5) 
£31,366 £39,713 -£8,347 5.009 4.968 0.041 
Table 1 presents the results of the first-order analysis. Total QALYs are presented for each regression 
analysis. Model 1 refers to the one-eye model (BSE). Model 2 refers to the one-eye model (WSE). 
Model 3 refers to the two-eye model, no interaction. Model 4 refers to the two-eye model, with 
interaction. Model 5 refers to the two-eye model (with blindness threshold). The results show that 
ranibizumab was the dominant strategy (more effective and less costly) compared with aflibercept. 
Results are based on 200,000 iterations. 
Abbreviations. QALY: quality-adjusted life year.  BSE: best seeing eye. WSE: worst seeing eye. 
 
 
Table 2. Second-order results (parameter uncertainty) 
 
Mean cost 
Incremental  
Cost (95% 
CI) 
Mean QALYs 
Incremental  
QALYs 
 Ranibizumab Aflibercept  Ranibizumab  Aflibercept  
BSE only 
(Model 1) 
£32,450 £39,597 
-£7,168 (-
£7,669, -
£6,667) 5.739 5.693 
 0.046 
(0.038, 
0.053) 
WSE only 
(Model 2) 
£32,539 £39,563 
-£7,016 (-
£7,492, -
£6,540) 4.460 4.424 
0.035 
(0.027, 
0.043) 
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Two eye, 
no 
interaction 
(Model 3) £32,732 £39,577 
-£6,846 (-
£7,273, -
£6,419) 5.158 5.109 
0.049 
(0.040, 
0.057) 
Two eye, 
with 
interaction 
(Model 4) £33,270 £40,071 
 -£6,811 (-
£7,244, -
£6,379) 5.096 5.057 
0.039 
(0.029, 
0.049) 
Two eye, 
with 
blindness 
threshold 
(Model 5) £33,116 £39,172 
-£6,051 (-
£6,474, -
£5,628) 5.160 5.122 
0.039 
(0.029, 
0.049) 
Table 2 presents the results of the second-order analysis. Model 1 refers to the one-eye model (BSE). 
Model 2 refers to the one-eye model (WSE). Model 3 refers to the two-eye model, no interaction. 
Model 4 refers to the two-eye model, with interaction. Model 5 refers to the two-eye model (with 
blindness threshold). The results show that ranibizumab was the dominant strategy (more effective and 
less costly) compared with aflibercept. Results are based on 100 estimations of cost-effectiveness, each 
based on 10,000 iterations of the model. 
Abbreviations. CI: confidence interval. QALY: quality-adjusted life year. BSE: best seeing eye. WSE: 
worst seeing eye. 
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